methylene blue has been researched along with Acute Confusional Senile Dementia in 59 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.69) | 18.2507 |
| 2000's | 7 (11.86) | 29.6817 |
| 2010's | 42 (71.19) | 24.3611 |
| 2020's | 9 (15.25) | 2.80 |
| Authors | Studies |
|---|---|
| Cisek, K; Honson, NS; Jensen, JR; Kuret, J | 1 |
| Bulic, B; Mandelkow, E; Pickhardt, M | 1 |
| Ge, S; Guan, J; Lin, JP; Liu, XH; Wang, T; Wu, MB; Yang, LR | 1 |
| Kumar, R; Pavlov, PF; Wang, L; Winblad, B | 1 |
| Albuquerque, HMT; Malafaia, D; Silva, AMS | 1 |
| Bai, K; Ding, Y; Han, G; Ji, Y; Sun, C; Yang, X; Zhang, H; Zhou, J | 1 |
| Aksinenko, AY; Bachurin, SO; Boltneva, NP; Dubova, LG; Epishina, TA; Fisenko, VP; Goreva, TV; Grigoriev, VV; Kovaleva, NV; Lushchekina, SV; Makhaeva, GF; Pushkareva, EA; Richardson, RJ; Rudakova, EV; Serkova, TP; Shevtsov, PN; Shevtsova, EF; Veselov, IM; Vinogradova, DV | 1 |
| Genrikhs, EE; Guschina, AS; Isaev, NK; Novikova, SV; Olshanskij, AS; Shedenkova, MO; Stavrovskaya, AV; Stelmashook, EV; Voronkov, DN; Yamshikova, NG | 1 |
| Gao, M; Gümüşdil, E; Han, Y; Huang, Y; Li, P; Liu, Y; Man, VH; Mao, H; Perrett, S; Pokhrel, P; Ramirez, LM; Su, Z; Wang, J; Wen, J; Wu, S; Ye, H; Zweckstetter, M | 1 |
| Lee, HE; Lee, JY; Lim, D; Lim, SM; Pae, AN | 1 |
| Baddeley, TC; Bentham, P; Bracoud, L; Ganesan, H; Gauthier, S; Hammel, J; Harrington, CR; Jia, J; Kook, K; Murray, AD; Riedel, G; Rubino, CM; Schelter, BO; Shiells, H; Staff, RT; Storey, JMD; Vuksanovic, V; Wischik, CM | 1 |
| Bartochowski, Z; Grossberg, GT; Hashweh, NN; Khoury, R | 1 |
| Cranston, A; Harrington, CR; Klein, J; Kondak, C; Lauer, D; Magbagbeolu, M; Melis, V; Niewiadomska, G; Riedel, G; Santos, RX; Schwab, K; Steczkowska, M; Theuring, F; Wischik, CM; Wydrych, M; Zadrozny, M | 1 |
| Calabrese, EJ; Kozumbo, WJ | 1 |
| Agrawal, K; Annadurai, N; Das, V; Džubák, P; Hajdúch, M | 1 |
| Chung, YJ; Lee, BI; Park, CB; Suh, YS; Yu, K | 1 |
| Weinstein, JD | 1 |
| Ahearn, T; Bentham, P; Bracoud, L; Davis, CS; Frisoni, GB; Gauthier, S; Hardlund, JH; Harrington, CR; Jia, J; Kook, KA; Marek, K; Moebius, HJ; Riedel, G; Schelter, BO; Seibyl, J; Shamsi, K; Staff, RT; Storey, JMD; Vuksanovic, V; Wilcock, GK; Wischik, CM; Wischik, DJ | 1 |
| Chen, Q; Du, Y; Feng, J; He, Q; Jin, Z; Li, F; Li, J; Liang, Z; Ling, D; Ren, R; Sun, J; Sun, X; Tian, M; Yu, H; Zhang, H; Zhang, K; Zhou, M | 1 |
| Berrocal, M; Corbacho, I; Gutierrez-Merino, C; Mata, AM | 1 |
| Al-Hilaly, YK; Baddeley, T; Harrington, CR; Pollack, SJ; Raulin, AC; Rickard, JE; Schellenberger, P; Serpell, LC; Simpson, M; Storey, JMD; Wischik, CM | 1 |
| Ishida, K; Kojima, S; Maeda, S; Nakamura, A; Saito, M; Soeda, Y; Takashima, A | 1 |
| Caetano, MS; da Cunha, EFF; de Castro, AA; Kuca, K; Leal, DHS; Nepovimova, E; Pereira, AF; Polisel, DA; Ramalho, TC; Soares, FV | 1 |
| Ballatore, C; Brunden, KR; Crowe, A; James, MJ; Lee, VM; Smith, AB; Trojanowski, JQ | 1 |
| Alescio-Lautier, B; Fauvelle, F; Filali, M; Manrique, C; Maunoir-Regimbal, S; Paban, V | 1 |
| Harvey, BH; Petzer, A; Petzer, JP | 1 |
| Barksdale, BR; Gonzalez-Lima, F; Rojas, JC | 1 |
| Hou, H; Kinoshita, N; Koyama, N; Maeda, M; Maruyama, N; Mori, T; Segawa, T; Tan, J; Town, T | 1 |
| Brinet, D; Glumm, S; Kaffy, J; Ongeri, S; Oukacine, F; Taverna, M | 1 |
| Baddeley, TC; Cheung, JK; Harrington, CR; Horsley, D; McCaffrey, J; Melis, V; Storey, JM; Wischik, CM | 1 |
| Bentham, P; Harrington, CR; Kook, KA; Murray, AD; Staff, RT; Storey, JM; Wischik, CM; Wischik, DJ | 1 |
| Abdel-Kader, RM; Hamdi, N; Zakaria, A | 1 |
| Clunas, S; Harrington, CR; Harrington, KA; Horsley, D; Ishaq, A; Kemp, SJ; Larch, CP; Marshall, C; Nicoll, SL; Rickard, JE; Simpson, M; Sinclair, JP; Storey, JM; Storey, LJ; Wischik, CM | 1 |
| Bakota, L; Brandt, R | 1 |
| Daniele, A; Greco, A; Imbimbo, BP; Logroscino, G; Lozupone, M; Panza, F; Santamato, A; Seripa, D; Solfrizzi, V; Zuliani, G | 1 |
| Barulli, MR; Bellomo, A; Daniele, A; Greco, A; Imbimbo, BP; Logroscino, G; Lozupone, M; Panza, F; Pilotto, A; Santamato, A; Seripa, D; Solfrizzi, V; Zecca, C | 1 |
| Wise, J | 1 |
| Ashford, JW; Huang, X; Inayathullah, M; Kim, KM; Lee, S; Liu, S; Rajadas, J; Sun, W; Tang, H | 1 |
| Li, L; Li, PJ; Lu, HL; Qin, L; Song, YJ; Yang, RL | 1 |
| Caramillo, EM; Echevarria, DJ | 1 |
| Hattori, M; In, Y; Ishida, T; Minoura, K; Sugino, E; Sumida, M; Taniguchi, T; Tomoo, K | 1 |
| Gura, T | 1 |
| Scheindlin, S | 1 |
| Lorke, DE; Oz, M; Petroianu, GA | 1 |
| Akiyama, H; Arai, T; Bachurin, SO; Buchman, VL; Goedert, M; Hasegawa, M; Kametani, F; Ninkina, N; Nonaka, T; Yamashita, M | 1 |
| Hasan, M; Lorke, DE; Oz, M; Petroianu, GA | 1 |
| Bandyopadhyay, B; Chang, E; Funk, KE; Honson, NS; Jensen, JR; Kim, S; Kuret, J; Naphade, S | 1 |
| Atamna, H; Kumar, R | 1 |
| Caccamo, A; Medina, DX; Oddo, S | 1 |
| Adler, H; Mandelkow, E; Pickhardt, M; Schirmer, RH | 1 |
| Dolan, PJ; Johnson, GV; Pritchard, SM; Vitkus, A | 1 |
| Gravitz, L | 1 |
| Al Mansouri, AS; Ashoor, A; Isaev, D; Keun-Hang, SY; Lorke, DE; Nurulain, SM; Oz, M; Petroianu, G | 1 |
| Lippa, CF; Ozudogru, SN | 1 |
| Appleby, BS; Cummings, JL; Milano, N; Nacopoulos, D; Zhong, K | 1 |
| Biberoglu, K; Chupakhin, V; Makhaeva, GF; Sezgin, Z; Tacal, O | 1 |
| Akoury, E; Biernat, J; Gajda, M; Mandelkow, E; Pickhardt, M; Zweckstetter, M | 1 |
| Edwards, PC; Harrington, CR; Lai, RY; Roth, M; Wischik, CM | 1 |
21 review(s) available for methylene blue and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Progress and developments in tau aggregation inhibitors for Alzheimer disease.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; Humans; Hydrogen Bonding; Models, Molecular; Protein Binding; Protein Conformation; Structure-Activity Relationship; tau Proteins | 2013 |
Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Drug Discovery; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents | 2019 |
Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance.
Topics: Alzheimer Disease; Animals; Benzodioxoles; Cholinesterase Inhibitors; Cholinesterases; Curcumin; Humans; Molecular Targeted Therapy; Neurofibrillary Tangles; Neuroprotective Agents; Phosphorylation; Plaque, Amyloid; Protein Aggregation, Pathological; Protein Processing, Post-Translational; Quinazolines; Receptors, N-Methyl-D-Aspartate; tau Proteins; Thiadiazoles | 2021 |
Amyloid-β and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review.
Topics: Alzheimer Disease; Aminoquinolines; Amyloid beta-Peptides; Curcumin; Heterocyclic Compounds, 4 or More Rings; Humans; Molecular Structure; Structure-Activity Relationship; Tacrine; tau Proteins | 2021 |
An evaluation of hydromethylthionine as a treatment option for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognitive Dysfunction; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Humans; Methylene Blue; Protein Aggregates; Randomized Controlled Trials as Topic; tau Proteins; Treatment Outcome | 2020 |
The hormetic dose-response mechanism: Nrf2 activation.
Topics: Alzheimer Disease; Animals; Drug Discovery; Hormesis; Humans; Light; Methylene Blue; Nervous System Diseases; NF-E2-Related Factor 2; Oxidative Stress; Phytochemicals; Protective Agents; Radiation, Ionizing | 2021 |
Microtubule affinity-regulating kinases are potential druggable targets for Alzheimer's disease.
Topics: Alzheimer Disease; Antigens, Bacterial; Azepines; Bacterial Proteins; Humans; Methylene Blue; Neurons; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyridines; Pyrroles; Staurosporine; tau Proteins | 2017 |
Non-conventional compounds with potential therapeutic effects against Alzheimer's disease.
Topics: Alzheimer Disease; Enzyme Inhibitors; Humans; Medicine, Chinese Traditional; Methylene Blue; Nanotechnology; Organophosphorus Compounds | 2019 |
Mitochondrial respiration as a target for neuroprotection and cognitive enhancement.
Topics: Alzheimer Disease; Cognition; Dose-Response Relationship, Drug; Humans; Ketone Bodies; Laser Therapy; Methylene Blue; Mitochondria | 2014 |
Tau Biology and Tau-Directed Therapies for Alzheimer's Disease.
Topics: Alzheimer Disease; Epothilones; Humans; Immunization, Passive; Methylene Blue; Molecular Targeted Therapy; Oligopeptides; Protein Aggregation, Pathological; tau Proteins | 2016 |
Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.
Topics: Alzheimer Disease; Clinical Trials as Topic; Humans; Methylene Blue; tau Proteins | 2016 |
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Brain; Evidence-Based Medicine; Humans; Methylene Blue; Molecular Targeted Therapy; Neuroprotective Agents; tau Proteins; Treatment Outcome | 2016 |
Alzheimer's disease in the zebrafish: where can we take it?
Topics: Alzheimer Disease; Animals; Dementia; Disease Models, Animal; Donepezil; Humans; Indans; Memantine; Methylene Blue; Piperidines; Rodentia; Species Specificity; Zebrafish | 2017 |
Methylene blue and Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cognition Disorders; Humans; Methylene Blue; Neurofibrillary Tangles; Neurons | 2009 |
Cellular and molecular actions of Methylene Blue in the nervous system.
Topics: Alzheimer Disease; Animals; Humans; Ifosfamide; Methemoglobinemia; Methylene Blue; Neurons | 2011 |
Modulation and detection of tau aggregation with small-molecule ligands.
Topics: Alzheimer Disease; Brain; Humans; Methylene Blue; Neurofibrillary Tangles; tau Proteins | 2009 |
Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase.
Topics: Alzheimer Disease; Animals; Electron Transport Complex IV; Humans; Methylene Blue; Mitochondria; Neuroprotective Agents | 2010 |
"Lest we forget you--methylene blue...".
Topics: Alzheimer Disease; Animals; Antimalarials; Humans; Methylene Blue; tau Proteins | 2011 |
The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Humans; Methylene Blue; Models, Biological; Neurofibrillary Tangles; Proteasome Endopeptidase Complex; tau Proteins | 2011 |
Disease modifying drugs targeting β-amyloid.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Enzyme Inhibitors; Glucagon-Like Peptides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Methylene Blue; Nootropic Agents | 2012 |
A review: treatment of Alzheimer's disease discovered in repurposed agents.
Topics: Aged; Alzheimer Disease; Anti-Asthmatic Agents; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressive Agents; Antihypertensive Agents; Antineoplastic Agents; Antiparkinson Agents; Antipsychotic Agents; Drug Discovery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Methylene Blue; Nicotine; Nicotinic Agonists | 2013 |
4 trial(s) available for methylene blue and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Atrophy; Brain; Cognitive Dysfunction; Dose-Response Relationship, Drug; Female; Humans; Male; Methylene Blue | 2019 |
Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cohort Studies; Double-Blind Method; Female; Humans; International Cooperation; Male; Mental Status and Dementia Tests; Methylene Blue; Middle Aged; Treatment Outcome | 2018 |
Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease.
Topics: Absorption, Physicochemical; Administration, Oral; Adolescent; Adult; Alzheimer Disease; Animals; Biological Transport; Brain; Dose-Response Relationship, Drug; Eating; Erythrocytes; Female; Humans; Male; Methylene Blue; Mice; Oxidation-Reduction; Protein Aggregation, Pathological; tau Proteins; Young Adult | 2015 |
Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Double-Blind Method; Erythrocyte Count; Female; Humans; Male; Methylene Blue; Neuroprotective Agents; Psychiatric Status Rating Scales; tau Proteins; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2015 |
34 other study(ies) available for methylene blue and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Ligand polarizability contributes to tau fibril binding affinity.
Topics: Alzheimer Disease; Benzothiazoles; Binding Sites; Humans; Indoles; Ligands; Oxindoles; Phenothiazines; Protein Binding; tau Proteins; Thiazoles | 2011 |
"Drug-Carrier" Synergy Therapy for Amyloid-β Clearance and Inhibition of Tau Phosphorylation via Biomimetic Lipid Nanocomposite Assembly.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Biomimetics; Drug Carriers; Lipids; Methylene Blue; Mice; Nanocomposites; Phosphorylation; tau Proteins | 2022 |
Conjugates of Methylene Blue with Cycloalkaneindoles as New Multifunctional Agents for Potential Treatment of Neurodegenerative Disease.
Topics: Alzheimer Disease; Calcium; Cholinesterase Inhibitors; Cholinesterases; Humans; Ligands; Methylene Blue; Neurodegenerative Diseases; Receptors, N-Methyl-D-Aspartate | 2022 |
Neuroprotective effects of methylene blue in streptozotocin-induced model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Hippocampus; Maze Learning; Methylene Blue; Neuroprotective Agents; Rats; Streptozocin | 2023 |
Methylene blue accelerates liquid-to-gel transition of tau condensates impacting tau function and pathology.
Topics: Alzheimer Disease; Amyloidogenic Proteins; Cytoskeleton; Humans; Methylene Blue; Phase Transition | 2023 |
Recent tau-targeted clinical strategies for the treatment of Alzheimer's disease.
Topics: Acetylation; Alzheimer Disease; Animals; Humans; Methylene Blue; Mice; Salicylates; Severity of Illness Index; tau Proteins | 2019 |
Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model.
Topics: Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Disease Models, Animal; Drug Interactions; Methylene Blue; Mice; Mice, Transgenic; Protein Aggregates; Rivastigmine; tau Proteins | 2020 |
Shedding Light on Alzheimer's β-Amyloidosis: Photosensitized Methylene Blue Inhibits Self-Assembly of β-Amyloid Peptides and Disintegrates Their Aggregates.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloidosis; Animals; Brain; Disease Models, Animal; Drosophila melanogaster; Humans; Light; Locomotion; Methylene Blue; Neuromuscular Junction; Neuroprotective Agents; Nootropic Agents; Oxidation-Reduction; Peptide Fragments; Photochemotherapy; Photosensitizing Agents; Protein Aggregates; Singlet Oxygen | 2017 |
A unique and promising combination of medications for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Dementia; Disease Progression; Drug Design; Drug Therapy, Combination; Humans; Inflammation; Methylene Blue; Neurons; Nicergoline; Oxidative Stress; Pentoxifylline; Pyridoxamine; Pyrimidines | 2017 |
Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Apoptosis; Cell Survival; Humans; Male; Methylene Blue; Molecular Structure; Nanocomposites; Rats; Rats, Sprague-Dawley; tau Proteins; Tumor Cells, Cultured | 2018 |
Methylene blue activates the PMCA activity and cross-interacts with amyloid β-peptide, blocking Aβ-mediated PMCA inhibition.
Topics: Adenosine Triphosphate; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Brain; Chlorocebus aethiops; COS Cells; Humans; Isoenzymes; Methylene Blue; Neuroprotective Agents; Plasma Membrane Calcium-Transporting ATPases; Protein Conformation; Saccharomyces cerevisiae; Sus scrofa; Synaptosomes | 2018 |
Cysteine-Independent Inhibition of Alzheimer's Disease-like Paired Helical Filament Assembly by Leuco-Methylthioninium (LMT).
Topics: Alzheimer Disease; Cysteine; Heparin; Humans; Methylene Blue; Molecular Structure; Neurofibrillary Tangles; Recombinant Proteins; Spectrum Analysis; tau Proteins | 2018 |
Methylene Blue Inhibits Formation of Tau Fibrils but not of Granular Tau Oligomers: A Plausible Key to Understanding Failure of a Clinical Trial for Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Disease Models, Animal; Methylene Blue; Mice; Neurofibrillary Tangles; Phosphorylation; tau Proteins | 2019 |
Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation.
Topics: Alzheimer Disease; Cysteine; Humans; Methylene Blue; Multiprotein Complexes; Oxidation-Reduction; tau Proteins | 2013 |
Therapeutic and preventive effects of methylene blue on Alzheimer's disease pathology in a transgenic mouse model.
Topics: Administration, Oral; Alanine; Alzheimer Disease; Amyloid beta-Peptides; Animals; Avoidance Learning; Cerebral Cortex; Discrimination, Psychological; Disease Models, Animal; Hippocampus; Injections, Intraperitoneal; Lactic Acid; Male; Methylene Blue; Mice; Mice, Transgenic; Mitochondria; Motor Activity; Nesting Behavior; Neuroprotective Agents | 2014 |
The interactions of azure B, a metabolite of methylene blue, with acetylcholinesterase and butyrylcholinesterase.
Topics: Acetylcholinesterase; Alzheimer Disease; Azure Stains; Butyrylcholinesterase; Cholinesterase Inhibitors; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Linear Models; Methylene Blue | 2014 |
Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Amyloidosis; Animals; Brain Diseases; Cerebral Cortex; CHO Cells; Cognition; Cricetinae; Cricetulus; Drug Evaluation, Preclinical; Humans; Male; Maze Learning; Methylene Blue; Mice, Inbred C57BL; Mice, Transgenic; Proteolysis | 2014 |
An improved capillary electrophoresis method for in vitro monitoring of the challenging early steps of Aβ1-42 peptide oligomerization: application to anti-Alzheimer's drug discovery.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Drug Discovery; Electrophoresis, Capillary; Humans; Kinetics; Methylene Blue; Peptide Fragments | 2014 |
Methylene Blue Improves Brain Mitochondrial ABAD Functions and Decreases Aβ in a Neuroinflammatory Alzheimer's Disease Mouse Model.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Alcohol Dehydrogenase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cell Survival; Cerebral Cortex; Disease Models, Animal; Estradiol; Inflammation; Lipopolysaccharides; Male; Methylene Blue; Mice; Mitochondria; Oxidative Stress; Reactive Oxygen Species | 2016 |
Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.
Topics: Alzheimer Disease; Animals; Brain; Cell Line; Humans; Methylene Blue; Mice; Mice, Transgenic; Models, Biological; Protein Aggregates; Protein Aggregation, Pathological; Protein Interaction Domains and Motifs; Proteolysis; Recombinant Proteins; tau Proteins | 2015 |
No "breakthrough" in Alzheimer's disease.
Topics: Alzheimer Disease; Humans; Mass Media; Methylene Blue; Randomized Controlled Trials as Topic; tau Proteins; Treatment Failure; United Kingdom; United States | 2016 |
Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Animals; Azure Stains; Drosophila Proteins; HEK293 Cells; Humans; Larva; Methylene Blue; Neuromuscular Junction; Phosphorylation; Protein Serine-Threonine Kinases; Synapses; tau Proteins | 2016 |
Methylene blue improves streptozotocin-induced memory deficit by restoring mitochondrial function in rats.
Topics: Adenosine Triphosphate; Alzheimer Disease; Animals; Avoidance Learning; CA1 Region, Hippocampal; Disease Models, Animal; Drug Evaluation, Preclinical; Electron Transport Complex IV; Lipid Peroxidation; Male; Memory Disorders; Methylene Blue; Mitochondria; Neurons; Neuroprotective Agents; Nootropic Agents; Random Allocation; Rats, Sprague-Dawley; Streptozocin | 2017 |
Different inhibitory response of cyanidin and methylene blue for filament formation of tau microtubule-binding domain.
Topics: Alzheimer Disease; Anthocyanins; Benzothiazoles; Cells, Cultured; Fluorescence; Fluorescent Dyes; Heparin; Humans; Methylene Blue; Microtubules; Protein Structure, Tertiary; tau Proteins; Thiazoles | 2008 |
Hope in Alzheimer's fight emerges from unexpected places.
Topics: Alzheimer Disease; Cognition; Humans; Indoles; Methylene Blue; Research | 2008 |
Something old... something blue.
Topics: Alzheimer Disease; Animals; Antimalarials; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Methemoglobinemia; Methylene Blue | 2008 |
New treatments in the pipeline for Alzheimer's.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Humans; Indoles; Methylene Blue | 2009 |
Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Cell Line; Dementia; DNA-Binding Proteins; Enzyme Inhibitors; Humans; Inclusion Bodies; Indoles; Methylene Blue | 2009 |
Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blotting, Western; Cognition Disorders; Disease Models, Animal; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Immunohistochemistry; Male; Methylene Blue; Mice; Mice, Transgenic; Proteasome Endopeptidase Complex; tau Proteins | 2011 |
Drugs: a tangled web of targets.
Topics: Alanine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azepines; Clinical Trials as Topic; Disease Progression; Genetic Therapy; Glycogen Synthase Kinase 3; Humans; Indoles; Memantine; Methylene Blue; Molecular Targeted Therapy; Nerve Growth Factor; Neurofibrillary Tangles; Phosphorylation; tau Proteins | 2011 |
Methylene blue inhibits the function of α7-nicotinic acetylcholine receptors.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Bungarotoxins; CA1 Region, Hippocampal; Enzyme Inhibitors; GABA Agents; gamma-Aminobutyric Acid; Humans; Male; Membrane Potentials; Methylene Blue; Nicotinic Antagonists; Oocytes; Patch-Clamp Techniques; Pyramidal Cells; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Xenopus laevis | 2012 |
Determination of binding points of methylene blue and cationic phenoxazine dyes on human butyrylcholinesterase.
Topics: Alzheimer Disease; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Coloring Agents; HEK293 Cells; Humans; Methylene Blue; Molecular Docking Simulation; Mutagenesis, Site-Directed; Oxazines; Protein Binding; Recombinant Proteins | 2013 |
Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Cysteine; Disease Models, Animal; Humans; Magnetic Resonance Spectroscopy; Methylene Blue; Oxidation-Reduction; Phenothiazines; Protein Binding; tau Proteins | 2013 |
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.
Topics: Alzheimer Disease; Humans; Macromolecular Substances; Methylene Blue; Peptide Fragments; Phenothiazines; Pronase; Protein Binding; tau Proteins | 1996 |